Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Pluristem Therapeutics: Strengths and Weaknesses

Rating Financials

Pluristem Therapeutics SectorUnited States

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Pluristem Therapeutics SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Pluristem Therapeutics SectorUnited States

Consensus

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

-

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Pluristem Therapeutics SectorUnited States

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

-

Rating Revisions

Pluristem Therapeutics SectorUnited States

Financial revisions

-

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

-

EPS revisions (7 days)

-

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
14.57M - - - - - -
45.48B
AAA
43.68B -
B
- -
43.09B
AAA
39.4B -
31.91B
A
17.31B - - - -
16.4B
BBB
14.24B
AA
13.28B
AA
Average 26.48B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. PLUR Stock
  4. Stock
  5. Ratings Pluristem Therapeutics
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!